These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7011110)

  • 1. The antihypertensive effects of a pure and selective serotonin-receptor blocking agent (R 41 468) in elderly patients.
    De Cree J; Leempoels J; De Cock W; Geukens H; Verhaegen H
    Angiology; 1981 Feb; 32(2):137-44. PubMed ID: 7011110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist.
    Weiner CP; Socol ML; Vaisrub N
    Am J Obstet Gynecol; 1984 Jul; 149(5):496-500. PubMed ID: 6377898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive properties of ketanserin in combination with beta-adrenergic blocking agents.
    Hedner T; Persson B
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S161-3. PubMed ID: 2412042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketanserin in essential hypertension: a double-blind, placebo-controlled study.
    Cameron HA; Ramsay LE
    Postgrad Med J; 1985 Jul; 61(717):583-6. PubMed ID: 3161013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension.
    Wing LM; Chalmers JP; West MJ; Bune AJ; Ayres B; Graham JR
    Clin Exp Hypertens A; 1984; 6(6):1107-17. PubMed ID: 6146414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trial of ketanserin in hypertension.
    McGourty JC; Silas JH; Cowen KJ
    Br J Clin Pharmacol; 1985 Jul; 20(1):37-40. PubMed ID: 3161531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
    Persson B; Gradin K; Pettersson A; Hedner T
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S22-4. PubMed ID: 2459509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with ketanserin and ritanserin in hypertensive patients.
    Hedner T; Persson B
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S44-8. PubMed ID: 2459514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive effects of chronic 5-hydroxytryptamine (5-HT2) receptor blockade with ketanserin in the spontaneously hypertensive rat.
    Pettersson A; Persson B; Henning M; Hedner T
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Aug; 327(1):43-7. PubMed ID: 6493349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker.
    Rosenthal J; Koehle W; Gruebel B; Fisher R
    J Hypertens Suppl; 1986 Apr; 4(1):S85-7. PubMed ID: 2871145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketanserin: haemodynamic effects and mechanism of action.
    Schalekamp MA; Woittiez AJ; Wenting GJ; van den Meiracker AH; Man in 't Veld AJ
    J Hypertens Suppl; 1986 Apr; 4(1):S7-12. PubMed ID: 2871144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of ketanserin and metoprolol in essential hypertension.
    Seedat YK; Parag KB
    S Afr Med J; 1985 Oct; 68(8):555-8. PubMed ID: 2931840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The acute antihypertensive effect of ketanserin increases with age.
    De Crée J; Hoing M; De Ryck M; Symoens J
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S126-7. PubMed ID: 2412033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.
    Hedner T; Persson B
    Br J Clin Pharmacol; 1984 Nov; 18(5):765-71. PubMed ID: 6150724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind comparison of ketanserin with atenolol: antihypertensive activity and effect on platelet function.
    Kirch W; Ohnhaus EE
    J Hypertens Suppl; 1986 Apr; 4(1):S67-71. PubMed ID: 2939216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J; Stott DJ; Robertson JI; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antihypertensive effects of ketanserin (R 41468), a novel 5-hydroxytryptamine-blocking agent, in patients with essential hypertension.
    De Crée J; Leempoels J; Geukens H; De Cock W; Verhaegen H
    Clin Sci (Lond); 1981 Dec; 61 Suppl 7():473s-476s. PubMed ID: 7032829
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.